| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1473-3099(11)70099-8 |
| P698 | PubMed publication ID | 21719349 |
| P50 | author | Mihai Netea | Q24517868 |
| Nima Rezaei | Q26464741 | ||
| P2093 | author name string | Mona Hedayat | |
| P2860 | cites work | MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4 | Q22009943 |
| Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide | Q24294695 | ||
| The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex | Q24316449 | ||
| Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer | Q24318972 | ||
| Antiviral actions of interferons | Q24550676 | ||
| Toll-like receptor signalling | Q24570126 | ||
| Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions | Q24656625 | ||
| Imiquimod for the treatment of genital warts: a quantitative systematic review | Q24799636 | ||
| Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells | Q24805624 | ||
| Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). | Q43078075 | ||
| Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children | Q43266982 | ||
| Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study | Q43652252 | ||
| Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection | Q43674566 | ||
| Mismatched double-stranded RNA, ampligen (poly(I) : poly(C12U)), demonstrates antiviral and immunostimulatory activities in HIV disease | Q43845419 | ||
| Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children | Q44016534 | ||
| Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease | Q44079686 | ||
| Topical 5% imiquimod long-term treatment of cutaneous warts resistant to standard therapy modalities | Q44129558 | ||
| Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. | Q44169635 | ||
| Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model | Q44833573 | ||
| Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. | Q44833577 | ||
| Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. | Q45384251 | ||
| CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years | Q45395440 | ||
| Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial | Q45405707 | ||
| Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection | Q45412267 | ||
| Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults | Q45423583 | ||
| CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. | Q45424221 | ||
| Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus | Q45596016 | ||
| MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). | Q46102734 | ||
| Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru | Q46448535 | ||
| New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. | Q47878245 | ||
| Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. | Q47942964 | ||
| TLR4 agonists as immunomodulatory agents | Q50076068 | ||
| Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis | Q50733321 | ||
| Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities | Q51030792 | ||
| Differential involvement of BB loops of toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4- versus TLR2-mediated signal transduction | Q52564845 | ||
| Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs | Q52677025 | ||
| Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529. | Q53933808 | ||
| Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model | Q54437931 | ||
| Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine | Q58736117 | ||
| Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy | Q60469287 | ||
| Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. | Q64944387 | ||
| Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex | Q69899888 | ||
| Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection | Q71692238 | ||
| Adjuvant activities of immune response modifier R-848: comparison with CpG ODN | Q73005808 | ||
| The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population | Q78424586 | ||
| Structure-activity relationship of synthetic toll-like receptor 4 agonists | Q79191160 | ||
| A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine | Q80049574 | ||
| Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin | Q80155644 | ||
| Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients | Q80238954 | ||
| Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine | Q80422012 | ||
| CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study | Q81205526 | ||
| Toll-like receptors, cytokines and HIV-1 | Q81588031 | ||
| Toll-like receptors: linking innate and adaptive immunity | Q81808287 | ||
| Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative tr | Q82939689 | ||
| Toll-like receptors and innate immunity | Q84418644 | ||
| Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine | Q84956904 | ||
| Vaccine adjuvants: scientific challenges and strategic initiatives | Q37403484 | ||
| New insight in LPS antagonist | Q37411627 | ||
| The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali | Q37456934 | ||
| Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. | Q37497786 | ||
| Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides | Q38289912 | ||
| Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response | Q38334354 | ||
| Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial | Q38373188 | ||
| Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model | Q39831611 | ||
| TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock | Q40065389 | ||
| Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. | Q40144102 | ||
| The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. | Q40203530 | ||
| Recombinant soluble forms of extracellular TLR4 domain and MD-2 inhibit lipopolysaccharide binding on cell surface and dampen lipopolysaccharide-induced pulmonary inflammation in mice | Q40206519 | ||
| Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity | Q40232989 | ||
| Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling | Q40489306 | ||
| CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. | Q40512685 | ||
| A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity | Q40755629 | ||
| CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses | Q40776605 | ||
| A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors | Q40888180 | ||
| Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia | Q41853897 | ||
| Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. | Q42993963 | ||
| A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). | Q43000679 | ||
| Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus | Q43041294 | ||
| Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C | Q27478117 | ||
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 | ||
| A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome | Q28251661 | ||
| Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial | Q28254031 | ||
| Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis | Q28254097 | ||
| Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix | Q28268292 | ||
| The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro | Q28319338 | ||
| Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults | Q28749215 | ||
| CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein | Q29615189 | ||
| Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | Q30366836 | ||
| Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. | Q30369510 | ||
| Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. | Q33211563 | ||
| Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate | Q33226922 | ||
| Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial | Q33316023 | ||
| Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria | Q33359552 | ||
| Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis | Q33509524 | ||
| Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial | Q33530106 | ||
| A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults | Q33598040 | ||
| Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. | Q33768989 | ||
| Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. | Q33788761 | ||
| Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. | Q33967257 | ||
| Crystal structure of human toll-like receptor 3 (TLR3) ectodomain | Q33987865 | ||
| Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults | Q34009363 | ||
| The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals | Q34021580 | ||
| HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates | Q34085119 | ||
| Toll-like receptor 2 controls expansion and function of regulatory T cells | Q34264024 | ||
| CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 | ||
| Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis | Q34334406 | ||
| Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs | Q34355633 | ||
| Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial | Q34359432 | ||
| Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection | Q34444955 | ||
| Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist | Q34531671 | ||
| CpG motifs in bacterial DNA and their immune effects | Q34542287 | ||
| GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives | Q34655188 | ||
| Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists | Q34942985 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7 | Q35143849 | ||
| Toll-like receptors and T-helper-1/T-helper-2 responses | Q35160610 | ||
| Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. | Q35277985 | ||
| Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents | Q35842681 | ||
| Inhibition of endotoxin response by synthetic TLR4 antagonists | Q35848256 | ||
| Aluminium compounds for use in vaccines | Q35915759 | ||
| Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome | Q36313592 | ||
| American Gastroenterological Association technical review on the management of hepatitis C. | Q36364156 | ||
| Therapeutic potential of Toll-like receptor 9 activation | Q36501229 | ||
| New hepatitis B vaccine formulated with an improved adjuvant system | Q36780117 | ||
| Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions | Q36967164 | ||
| Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant | Q36973053 | ||
| Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation | Q37004584 | ||
| Cell-penetrating peptides for drug delivery across membrane barriers | Q37039034 | ||
| Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues | Q37044185 | ||
| Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates | Q37051021 | ||
| TLR3: interferon induction by double-stranded RNA including poly(I:C). | Q37080631 | ||
| Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant | Q37109519 | ||
| Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. | Q37114768 | ||
| A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | Q37154750 | ||
| Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases | Q37169130 | ||
| Structures of TLR-ligand complexes | Q37201808 | ||
| Structures of the toll-like receptor family and its ligand complexes | Q37242985 | ||
| Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial | Q37253541 | ||
| Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond | Q37286716 | ||
| Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer | Q37387913 | ||
| The roles of TLRs, RLRs and NLRs in pathogen recognition | Q37402176 | ||
| P433 | issue | 9 | |
| P921 | main subject | toll-like receptor | Q408004 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 702-712 | |
| P577 | publication date | 2011-06-28 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases | |
| P478 | volume | 11 |
| Q36075829 | A Toll-Like Receptor 5 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-Associated Pneumococcal Mouse Infections. |
| Q39433199 | A synthetic lipid A mimetic modulates human TLR4 activity |
| Q37130755 | A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease |
| Q92404048 | A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection |
| Q55017727 | Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy. |
| Q34700900 | Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients |
| Q38260235 | Antiviral drug discovery: broad-spectrum drugs from nature |
| Q38647007 | Blockade of myeloid differentiation protein 2 prevents obesity-induced inflammation and nephropathy. |
| Q42229127 | Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension |
| Q21134745 | Charting the NF-κB pathway interactome map |
| Q34675128 | Combined TLR7/8 and TLR9 Ligands Potentiate the Activity of a Schistosoma japonicum DNA Vaccine |
| Q38270733 | Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses |
| Q27025519 | Controversial role of toll-like receptors in acute pancreatitis |
| Q37437301 | Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment |
| Q58796655 | Fibroblast growth factor receptor 1 antagonism attenuates lipopolysaccharide-induced activation of hepatic stellate cells via suppressing inflammation |
| Q34255700 | IBD—what role do Proteobacteria play? |
| Q37199493 | Immune activation and collateral damage in AIDS pathogenesis. |
| Q38111096 | Immune modulation by genetic modification of dendritic cells with lentiviral vectors. |
| Q38242227 | Immunological and technical considerations in application of alginate-based microencapsulation systems |
| Q61453473 | Immunomodulatory and Anti-Inflammatory Phytochemicals for the Treatment of Inflammatory Bowel Disease (IBD): - Turning Strong Rationale into Strong Evidence? |
| Q34950159 | Impaired blood dendritic cell numbers and functions after aneurysmal subarachnoid hemorrhage |
| Q38747644 | Implications of Toll-like receptors in Ebola infection |
| Q36996953 | Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin. |
| Q52649839 | Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus. |
| Q58792997 | Inhibition of Epidermal Growth Factor Receptor (EGFR) Reduces Lipopolysaccharide (LPS)-Induced Activation and Inflammatory Cytokines in Hepatic Stellate Cells In Vitro |
| Q38557048 | Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics |
| Q36511529 | Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly |
| Q47553095 | Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. |
| Q98224393 | Interactions of the Brain Renin-Angiotensin-System (RAS) and Inflammation in the Sensitization of Hypertension |
| Q38219023 | Intervention on toll-like receptors in pancreatic cancer |
| Q38067461 | Intestinal colonization resistance |
| Q50990734 | MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway |
| Q38040302 | MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. |
| Q40752357 | Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. |
| Q92714573 | Matrine alleviates imiquimod-induced psoriasiform dermatitis in BALB/c mice via dendritic cell regulation |
| Q64097188 | Molecular mechanisms in progression of HPV-associated cervical carcinogenesis |
| Q41554436 | Nanoparticles modify dendritic cell homeostasis and induce non-specific effects on immunity to malaria |
| Q38148590 | Reciprocal effects of Toll-like receptors and miRNAs on biological processes in human health and disease: a systematic review |
| Q38047077 | Regulators of innate immunity as novel targets for panviral therapeutics |
| Q36430758 | Role of TLR4/NADPH oxidase/ROS-activated p38 MAPK in VCAM-1 expression induced by lipopolysaccharide in human renal mesangial cells |
| Q35665349 | Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection |
| Q38419929 | Role of Toll-like receptor/MYD88 signaling in neurodegenerative diseases |
| Q44488921 | Role of human Toll-like receptors in naturally occurring influenza A infections |
| Q92714386 | Schisandrin B attenuates lipopolysaccharide-induced activation of hepatic stellate cells through Nrf-2-activating anti-oxidative activity |
| Q38695565 | Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling. |
| Q42362538 | Sepsis-Induced Cardiomyopathy: Mechanisms and Treatments |
| Q43842687 | Severe Pneumonia Mortality in Elderly Patients Is Associated With Downregulation of Toll-like Receptors 2 and 4 on Monocytes |
| Q40931701 | TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection |
| Q39432584 | Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. |
| Q37952783 | The 2011 Nobel Prize in Physiology or Medicine |
| Q35838023 | The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development |
| Q89700559 | The role of TLRs in cervical cancer with HPV infection: a review |
| Q38665495 | The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency |
| Q38881534 | Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis |
| Q35110074 | Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension |
| Q38053492 | Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities |
| Q38123280 | Type I interferon and lymphangiogenesis in the HSV-1 infected cornea – Are they beneficial to the host? |
| Q35211600 | Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis |
| Q39345885 | Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo |
Search more.